This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Background Hypertrophic cardiomyopathy (HCM) is commonly associated with atrialfibrillation (AF), but its impact on outcomes in real-world practice is uncertain. Patients with AF had a higher annual incidence of stroke/transient ischaemic attack (2.6 Methods Overall, 1739 adult patients with HCM (40.9% vs 1.7%, p=0.053).
Atrialfibrillation (AFib) is a common heart rhythm disorder characterized by an irregular and often rapid heartbeat. This condition can lead to various complications, including stroke and heart failure, making it essential to understand its causes, symptoms, and AFib treatment options. What is AtrialFibrillation?
Background Atrialfibrillation (AF) and acute myocardial infarction (AMI) share risk factors and are bidirectionally associated. Several studies found higher risks of outcomes in individuals with both conditions. Whether the risks of outcomes differ according to temporal order of AF and AMI is unclear.
This review provides information about the current evidence-base for screening for atrialfibrillation (AF). Finally, novel methods to refine the population to whom AF screening should be offered, which may improve clinical and cost-effectiveness, are considered.
Outcomes of ablation with the FARAPULSE PFA System – a nonthermal treatment in which electric fields selectively ablate heart tissue – will be compared to outcomes following use of anti-arrhythmic drug (AAD) therapy, which is commonly prescribed for patients living with persistent AF. Circulation.
IntroductionAtrial fibrillation (AF) is a prevalent cardiac arrhythmia and a significant contributor to cardioembolic stroke, a condition closely linked to cognitive decline. However, research reveals that AF itself is independently associated with an increased risk of cognitive impairment.
Atrialfibrillation is the most common cardiac arrhythmia worldwide with around 59 million people concerned in 2019. This irregular heartbeat is associated with increased risks of heart failure, dementia and stroke. It constitutes a significant burden to healthcare systems, making its early detection and treatment a major goal.
BackgroundAn increased risk of recurrent stroke is noted in patients with atrialfibrillation despite direct oral anticoagulant (DOAC) use. A total of 84 patients experienced recurrent ischemic stroke after switching to different oral anticoagulants, with a total follow‐up time of 14 years. 0.41] for rivaroxaban).ConclusionsIn
Stroke recovery is a challenging process that extends for months after hospital discharge. To improve outcomes and be in compliance with new regulations, it's crucial to better identify and address these issues during the recovery period. After the stroke, I had new prescriptions, and this was the first obstacle for me.
Background Efforts to maintain sinus rhythm in patients with persistent atrialfibrillation (PsAF) remain challenging, with suboptimal long-term outcomes. At 36 months, all patients were alive with no new stroke/transient ischaemic attack (TIA). All were longstanding persistent.
Sarcopenia, a progressive skeletal muscle disorder, is associated with adverse outcomes in various cardiovascular conditions. However, its impact on clinical outcomes, especially bleeding and strokeoutcomes, in patients with atrialfibrillation (AF) remains unclear.
Patients with atrialfibrillation, particularly older patients, are frequently at a high risk of bleeding. In patients with atrialfibrillation, abelacimab reduced rates of bleeding relative to rivaroxaban regardless of bleeding risk, with greater absolute safety benefit in those at higher bleeding risk.
Atrialfibrillation (AF) often leads to larger cerebral infarcts due to cardioembolic events. Thrombectomy has emerged as a key intervention for acute ischemic stroke caused by large vessel occlusions. However, disparities in thrombectomy utilization and outcomes in patients with AF-associated strokes remain underexplored.
Atrialfibrillation is the most common sustained arrhythmia. Females with atrialfibrillation have been known to have an increased risk of stroke. However, racial disparities in outcomes in atrialfibrillation patients have been less studied.
Lone atrialfibrillation (AF) has been defined as a subset of atrialfibrillation that occurs in younger patients with no other known cardiac disease or risk factors. Patient with lone AF have been shown to experience fewer cardiovascular events, including stroke and myocardial infarctions.
Catheter ablation of atrialfibrillation (AF) is the preferred strategy for improving survival and reducing heart failure (HF) hospitalizations in patients with heart failure with reduced ejection fraction (HFrEF) and AF.
BackgroundThrombocytopenia is often associated with adverse outcomes in patients with atrialfibrillation. ResultsA total of 12 studies included 73,824 patients with atrialfibrillation (average age: 72.67, males: 42,275, 57.3%), among them, there were 7,673 patients combined with thrombocytopenia.
18, 2024 — Abbott recently announced new data for the Amplatzer Amulet Left Atrial Appendage (LAA) Occluder to treat people with atrialfibrillation (AFib) who are at an increased risk of stroke. A statistically significant lower number of fatal or disabling strokes with Amulet (22 vs. 39). 16-18, 2024).
Atrialfibrillation (AF) is associated with stroke, heart failure and mortality. Early detection and intervention reduces the risk of adverse outcomes. Artificial-intelligence enhanced electrocardiography (AI-ECG) is a relatively new and promising methodology for the prediction of incident atrialfibrillation.
Obese patients with atrialfibrillation (AF) are at an increased risk of thromboembolic and bleeding events due to a prothrombotic state and comorbidities such as hypertension and diabetes. This study compares 5-year outcomes of left atrial appendage occlusion (LAAO) versus DOACs in patients with AF and Obesity.
Obese patients with atrialfibrillation (AF) are at an increased risk of thromboembolic and bleeding events due to a prothrombotic state and comorbidities such as hypertension and diabetes. This study compares 5-year outcomes of left atrial appendage occlusion (LAAO) versus DOACs in patients with AF and Obesity.
Objective Implantable loop recorders (ILRs) are increasingly used for long-term rhythm monitoring after ischaemic and cryptogenic stroke, with the goal of detecting atrialfibrillation (AF) and subsequent initiation of oral anticoagulation to reduce risk of adverse clinical outcomes. Mean age was 69.9 (SD years and 53.5%
BackgroundThe impact of atrialfibrillation (AF) on the clinical outcomes in patients with acute ischemic stroke (AIS) who received endovascular thrombectomy remains unclear. Data were meta‐analyzed to compare the outcomes among patients with AIS with and without AF who received endovascular thrombectomy.
Introduction Atrialfibrillation (AF) is associated with a fivefold increased risk of stroke. Oral anticoagulation reduces the risk of stroke, but AF is elusive.
BackgroundAs the population ages, atrialfibrillation (AF) prevalence increases, but data on optimal oral anticoagulation (OAC) in patients 80 years remain limited. Data were analyzed by age for outcomes and risk factors for predefined end points.ResultsPatients 80 years comprised 32.2% of AF cases. of AF cases. versus 70.5%,P=0.0070).
Background The value of empirical superior vena cava isolation (SVCI) following pulmonary vein isolation (PVI) to improve the efficacy of radiofrequency catheter ablation (RFCA) for paroxysmal atrialfibrillation (PAF) remains controversial.
Background Atrialfibrillation (AF) is the most common cardiac arrhythmia and is associated with a high risk of stroke. Finally, four indicators were included, namely, previous stroke/transient ischaemic attack (OR = 4.25, 95% CI = 1.57–12.23, 12.23, P = 0.006), left atrial volume index (LAVI) (OR = 1.04, 95% CI = 1.01–1.06,
Atrialfibrillation (AF) is the most common sustained cardiac arrhythmia in adults, leading to significant cardiovascular complications such as ischemic stroke, heart failure, and myocardial infarction. Pulmonary vein isolation (PVI) is a well-established treatment for rhythm control in patients with AF.
Titled "Real-world Data Affirms Safety and Effectiveness of Low/Zero Fluoroscopy AtrialFibrillation Ablation," the study was presented as a late-breaker at the 29th Annual International AF Symposium. Real-world Data Affirms Safety and Effectiveness of Low/Zero Fluoroscopy AtrialFibrillation Ablation [abstract].
Bernard's Heart & Vascular Center , Jonesboro, Arkansas) mark a significant milestone in the pursuit of innovative solutions for non-valvular atrialfibrillation (NVAF) treatment. Patients with NVAF deemed appropriate for LAAX to reduce the risk of stroke and systemic embolism, will participate in this research effort.
Atrialfibrillation (AF) is a common arrhythmia in patients with heart failure (HF). The coexistence of these conditions can further induce structural changes and result in worsened outcomes such as stroke, HF decompensation, poorly controlled AF, and mortality [1].
Stroke, Volume 55, Issue Suppl_1 , Page ATMP87-ATMP87, February 1, 2024. Background and purpose:Because the biochemical composition of thrombus changes after formation over time, thrombus maturation in the left atrium may affect clot compositions in ischemic stroke with atrialfibrillation (AF).
Stroke: Vascular and Interventional Neurology, Volume 4, Issue 6 , November 1, 2024. Data on patients with acute ischemic stroke from the Third China National Stroke Registry were analyzed. Patients with preexisting heart diseases had higherprevalence of moderate or severe stroke at admission (4.7%
Background:While anticoagulation is crucial for atrialfibrillation (AF) patients to prevent ischemic events, those with thrombocytopenia have a potential increased risk of bleeding. The primary outcome was all-cause inpatient mortality. There was no significant difference in ischemic stroke risk (aOR 0.67, 95% CI 0.37-1.21,
Background Evaluating outcomes of concurrent Cox-Maze procedures in elderly patients undergoing high-risk cardiac surgery. Mehods We retrospectively identified patients aged over 70 years with AtrialFibrillation (AF) from 2011 to 2017 who had two or more other cardiac procedures. They were subdivided into two groups: 1.
BackgroundDespite proven efficacy and safety of direct oral anticoagulants (DOACs) over warfarin in patients with atrialfibrillation (AF), data on patients with AF and valvular heart disease remain scarce. The primary effectiveness outcomes were ischemic stroke or systemic embolism, and bleeding for safety.
Stroke, Volume 55, Issue Suppl_1 , Page ATP269-ATP269, February 1, 2024. The association between AF and IS outcomes differed by IS therapy (Table 1). AF patients had an increased odds of a worse mRS (Ordinal OR 2.05, 95% CI 1.14-3.71), 3.71), but not after adjustment (Ordinal OR 1.07, 95% CI 0.52-2.20). respectively).
The introduction of Bruton Tyrosine Kinase inhibitors (BTKi) to the Chronic Lymphocytic Leukemia (CLL) treatment armamentarium has facilitated a significant improvement in overall outcomes. Incident atrialfibrillation (AF) has been identified as the most common reason for discontinuation of BTKi, limiting therapeutic utility of these agents.
Atrialfibrillation (AF) is associated with multiple adverse outcomes, including stroke, heart failure, and sudden death. Its accurate and timely diagnosis is crucial for effective treatment, prevention of stroke and systemic embolization in patients with AF and in other hand might affect AF treatment plan.
Stroke, Volume 55, Issue Suppl_1 , Page ATP230-ATP230, February 1, 2024. Introduction:Atrial fibrillation (AF) and cancer are both independently associated with worse outcomes in patients with acute ischemic stroke. Few studies have evaluated the impact of AF on outcomes of cancer-related stroke.
Atrialfibrillation often shortened to AFib is an irregular and often rapid heart rhythm that can lead to serious health complications. In some cases, AFib can also increase the risk of stroke, blood clots and heart failure. The post How to Prevent an AtrialFibrillation Attack appeared first on AMS Cardiology.
Asymptomatic cerebral emboli (ACE) can occur in patients undergoing an atrialfibrillation (AF) ablation, and has been studied extensively for radiofrequency ablation procedures. However, recent trials using PFA catheters have paused or terminated early due to concerns for cerebral embolism or ischemic stroke.
40
40
Input your email to sign up, or if you already have an account, log in here!
Enter your email address to reset your password. A temporary password will be e‑mailed to you.
We organize all of the trending information in your field so you don't have to. Join thousands of users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
88 
Let's personalize your content